Alkermes (NASDAQ:ALKS) is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes’ portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.
Alkermes’ commercial franchise features several approved products. Vivitrol, a once-monthly injectable therapy for the prevention of relapse to opioid dependence following detoxification and for the treatment of alcohol dependence, represents one of the company’s cornerstone offerings. In partnership with other pharmaceutical firms, Alkermes also supports the development and commercialization of therapies such as ARISTADA (aripiprazole lauroxil) for schizophrenia and Lybalvi (olanzapine/samidorphan) for schizophrenia and bipolar I disorder. These collaborations leverage Alkermes’ formulation and delivery platforms to optimize drug release profiles and enhance patient adherence.
The company’s research and development efforts are anchored by two proprietary drug delivery platforms: ALKS 2680 microsphere technology for sustained-release injectable formulations and ATRIGEL depot technology for biodegradable, polymer-based delivery. Alkermes’ R&D pipeline includes a diverse array of small molecules and biologics targeting CNS disorders, with programs in varying stages of clinical development. These assets reflect the company’s commitment to advancing long-acting therapies that can reduce dosing frequency and improve the overall patient experience.
Established in 1987, Alkermes maintains dual headquarters in Dublin, Ireland, and Waltham, Massachusetts, and operates manufacturing facilities in Ireland and the United States. The company’s leadership is headed by Chief Executive Officer Richard F. Pops, who has overseen its growth from a research-stage enterprise into a global biopharmaceutical organization. Alkermes continues to collaborate with academic institutions, patient advocacy groups and industry partners to expand access to therapies for CNS disorders worldwide.
